QR-504a

Phase 1Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fuchs Endothelial Corneal Dystrophy

Conditions

Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases, LRS, Descemet's Membrane Disorder

Trial Timeline

Aug 10, 2021 → Apr 12, 2022

About QR-504a

QR-504a is a phase 1 stage product being developed by ProQR for Fuchs Endothelial Corneal Dystrophy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05052554. Target conditions include Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases.

Hype Score Breakdown

Clinical
6
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05052554Phase 1Withdrawn

Competing Products

1 competing product in Fuchs Endothelial Corneal Dystrophy

See all competitors
ProductCompanyStageHype Score
DT-168Design TherapeuticsPhase 2
36